A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting

Molecular Therapy

Volumn 10, Issue 5, 2004, Pages 958-966

  Chiocca, E Antonio ^a   Abbed, Khalid M ^a   Tatter, Stephen ^a   Louis, David N ^a   Hochberg, Fred H ^a   Barker, Fred ^a   Kracher, Jean ^a   Grossman, Stuart A ^a   Fisher, Joy D ^a   Carson, Kathryn ^a   Rosenblum, Mark ^a   Mikkelsen, Tom ^a   Olson, Jeff ^a   Markert, James ^a   Rosenfeld, Steven ^a   Nabors, L Burt ^a   Brem, Steven ^a   Phuphanich, Surasak ^a   Freeman, Scott ^b   Kaplan, Rick ^c   Zwiebel, James ^c   more..

^a NABTT CNS Consortium   (United States)

^b ONYX PHARMACEUTICALS   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Adenovirus; Brain tumor; Clinical trial; Conditionally replicating adenoviruses; Experimental therapy; Gene therapy; Glioma; Oncolytic virus; ONYX 015; Virotherapy

Indexed keywords

ALANINE AMINOTRANSFERASE; CARMUSTINE; E1B PROTEIN; NITROSOUREA; ONCOLYTIC VIRUS; ONYX 015;

ADENOVIRUS; ADULT; AGED; ARTICLE; ATAXIA; CANCER GROWTH; CANCER PATIENT; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CELL INFILTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DYSGRAPHIA; DYSLEXIA; EMBOLISM; EXPRESSION VECTOR; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; GLIOBLASTOMA; HEADACHE; HUMAN; HYDROCEPHALUS; HYPERTENSION; HYPONATREMIA; KIDNEY FUNCTION; LIVER FUNCTION; LIVER TOXICITY; LYMPHOCYTIC INFILTRATION; MALE; MAXIMUM TOLERATED DOSE; MOTOR NEUROPATHY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHYSICAL EXAMINATION; SURVIVAL TIME; THROMBOSIS; VOMITING;

ADENOVIRIDAE; ADENOVIRUS E1B PROTEINS; ADULT; AGED; BRAIN; BRAIN NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE THERAPY; GENETIC VECTORS; GLIOMA; HUMANS; INJECTIONS, INTRALESIONAL; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; VIRUS REPLICATION;

ADENOVIRIDAE;

EID: 7044228126     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2004.07.021     Document Type: Article

References (34)

1. P. Kleihues et al. The WHO classification of tumors of the nervous system J. Neuropathol. Exp. Neurol. 61 2002 215-225
2. M.D. Prados V. Levin Biology and treatment of malignant glioma Semin. Oncol. 27 2000 1-10
3. M.D. Prados Future directions in the treatment of malignant gliomas with temozolomide Semin. Oncol. 27 2000 41-46
4. W.K. Yung Temozolomide in malignant gliomas Semin. Oncol. 27 2000 27-34
5. M.G. Castro et al. Current and future strategies for the treatment of malignant brain tumors Pharmacol. Ther. 98 2003 71-108
6. E.A. Chiocca Oncolytic viruses Nat. Rev. Cancer 2 2002 938-950
7. D. Kirn R.L. Martuza J. Zwiebel Replication-selective virotherapy for cancer: Biological principles, risk management and future directions Nat. Med. 7 2001 781-787
8. J.R. Bischoff et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells Science 274 1996 373-376
9. S.J. Edwards et al. Evidence that replication of the antitumor adenovirus ONYX-015 is not controlled by the p53 and p14(ARF) tumor suppressor genes J. Virol. 76 2002 12483-12490
10. J. Nemunaitis et al. Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients Cancer Gene Ther. 10 2003 341-352
11. O. Hamid et al. Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer J. Clin. Oncol. 21 2003 1498-1504
12. D. Makower et al. Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies Clin. Cancer Res. 9 2003 693-702
13. J.R. Hecht et al. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma Clin. Cancer Res. 9 2003 555-561
14. R.S. Warren D.H. Kirn Liver-directed viral therapy for cancer p53-targeted adenoviruses and beyond Surg. Oncol. Clin. North Am. 11 2002 571-588, vi
15. T. Reid et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): Phase II viral, immunologic, and clinical endpoints Cancer Res. 62 2002 6070-6079
16. P.A. Vasey et al. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer J. Clin. Oncol. 20 2002 1562-1569
17. T. Reid et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: A phase I trial Gene Ther. 8 2001 1618-1626
18. J. Nemunaitis et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: Safety, feasibility and biological activity Gene Ther. 8 2001 746-759
19. S. Mulvihill et al. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: A phase I trial Gene Ther. 8 2001 308-315
20. J. Nemunaitis et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer J. Clin. Oncol. 19 2001 289-298
21. J.P. Lamont J. Nemunaitis J.A. Kuhn S.A. Landers T.M. McCarty A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience) Ann. Surg. Oncol. 7 2000 588-592
22. F.R. Khuri et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Nat. Med. 6 2000 879-885
23. I. Ganly et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer Clin. Cancer Res. 6 2000 798-806
24. J.M. Markert et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial Gene Ther. 7 2000 867-874
25. V. Papanastassiou et al. The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: A proof of principle study Gene Ther. 9 2002 398-406
26. R. Rampling et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma Gene Ther. 7 2000 859-866
27. T.W. Trask et al. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors Mol. Ther. 1 2000 195-203
28. P.S. Smitt M. Driesse J. Wolbers M. Kros C. Avezaat Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir Mol. Ther. 7 2003 851-858
29. I.M. Germano J. Fable S.H. Gultekin A. Silvers Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: Preliminary results of a phase I trial in patients with recurrent malignant gliomas J. Neurooncol. 65 2003 279-289
30. F.F. Lang et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: Biological and clinical results J. Clin. Oncol. 21 2003 2508-2518
31. R.A. Dewey et al. Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trials Nat. Med. 5 1999 1256-1263
32. E.J. Boviatsis et al. Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors Hum. Gene Ther. 5 1994 183-191
33. A.P. Byrnes J.E. Rusby M.J. Wood H.M. Charlton Adenovirus gene transfer causes inflammation in the brain Neuroscience 66 1995 1015-1024
34. N.R. Bhat F. Fan Adenovirus infection induces microglial activation: involvement of mitogen-activated protein kinase pathways Brain Res. 948 2002 93-101